ArticleEClinicalMedicine2024

Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.

Xiaohua Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.